Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4609531 | 1.00 | MAPK14 (0.55) | MAPK14ALDH1A1NPC1RAB9ATP53 | |
| SCHEMBL4610429 | 0.97 | MAPK14 (0.56) | MAPK14ALDH1A1NPC1RAB9ATP53 | |
| SCHEMBL4610423 | 0.97 | MAPK14 (0.56) | MAPK14ALDH1A1NPC1RAB9ATP53 | |
| SCHEMBL4608671 | 0.94 | MAPK14 (0.54) | MAPK14ALDH1A1NPC1RAB9ATP53 | |
| SCHEMBL4608667 | 0.94 | MAPK14 (0.54) | MAPK14ALDH1A1NPC1RAB9ATP53 | |
| SCHEMBL4609069 | 0.94 | MAPK14 (0.56) | MAPK14ALDH1A1NPC1RAB9ATP53 | |
| SCHEMBL4609072 | 0.94 | MAPK14 (0.56) | MAPK14ALDH1A1NPC1RAB9ATP53 | |
| SCHEMBL4623446 | 0.94 | MAPK14 (0.57) | MAPK14ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL4623451 | 0.94 | MAPK14 (0.57) | MAPK14ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL4609384 | 0.93 | MAPK14 (0.55) | MAPK14ALDH1A1NPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449474-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1747204-B1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | PROCTER & GAMBLE (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1747204-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | The Procter and Gamble Company (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005105758-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | IL1B, IL1A, IL6 | MAPK14 2674/4885ALDH1A1 455/4885NPC1 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.